Daiichi Sankyo and AstraZeneca's Enhertu has been cleared for previously-untreated HER2-positive breast cancer in the US, becoming the first new first-line option in more than a decade. The FDA ...
AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer, including a 44% improvement in progression-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback